CIPROFLOXACIN HYDROCHLORIDE

Post-LOE

ciprofloxacin hydrochloride

Novartis

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Jun 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CIPROFLOXACIN HYDROCHLORIDE (ciprofloxacin hydrochloride) by Novartis is [see ] . Approved for infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: acute otitis media (aom) in pediatric patients (age 6 months, older) with tympanostomy tubes due to staphylococcus aureus, streptococcus pneumoniae and 3 more indications. First approved in 2004.

Drug data last refreshed 18h ago

Mechanism of Action

[see ] . Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

Indications (6)

infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 months older) with tympanostomy tubes due to Staphylococcus aureus

Worked on CIPROFLOXACIN HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.